Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see .30 break.
ATOM $24.40 I think this takes out $30 soon. 500 Jan. $25 call options were bought on the open Friday at $5.20. At the end of the day I was able to grab a few at $5. Also holding commons and a few Oct. $30's. Here's a video from Loe Basenese talking about ATOM at the 16:40 mark.
https://basenesegroup.wistia.com/medias/vkjw5ocki0
grabbed some lotto Oct. 2.50 calls @ .22 jic....thanks
kt
I agree! I haven't bought any SDRDW. Easier and cheaper to buy SDRWW and the expire at the same time. Seems to me they should be trading around the same price.
I also own a little of the commons. Great potential on all these going forward imo.
kt
I was a little late to the party but I grabbed a bunch at .03 the last few weeks. SDRWW
kt
The only difference I'm seeing in these warrants is that series A has over twice the amount OS. They both expire the same date and around the same price. Why is one higher than the other.....lower OS?
The Company has issued approximately 4.9 million Series A warrants and 2.1 million Series B warrants that are exercisable until October 4, 2022 for one share of common stock per warrant at initial prices of $41.34 and $42.03 per share, respectively, subject to adjustments pursuant to the terms of the warrants, to certain holders of general unsecured claims as defined in the Plan. The warrants contain customary anti-dilution adjustments in the event of any stock split, reverse stock split, reclassification, stock dividend or other distributions.
NP. I'm holding a few and that gave me a little scare and
I had to check again lol. Have a great day!
kt
It happens, especially being a bio. I should know better than to invest in these as this is the second one to bite my ass. Live and learn.....never put your money into someone else's hands(FDA)!
kt
Wow...that's really strange. Very cool to be able to capture that in video.
Your daughter sounds about the age of my granddaughter....boy do I feel old. :)
kt
Totally agree! Well put Trader59.
kt
The FDA will not approve a therapeutic that works. It's all about vaccines! Pretty sad!
kt
$HGEN declined EUA
https://ir.humanigen.com/English/news/news-details/2021/FDA-has-declined-Humanigens-Emergency-Use-Authorization-EUA-Request-for-Lenzilumab-in-Hospitalized-COVID-19-Patients/default.aspx
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today the U.S. FDA has declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients. In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19.
“We remain committed to bringing lenzilumab to patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chief Executive Officer, Humanigen. “We believe the ongoing ACTIV-5/BET-B trial, which has been advanced to enroll up to 500 patients, may provide additional safety and efficacy data sufficient to support our efforts to obtain an EUA to treat hospitalized COVID-19 patients.”
Nice volume the last hour! :)
Telcon RF Pharma, IRB Approval for Domestic Clinical Trial of ‘Lenzilumab’, a COVID-19 Treatment
https://view.asiae.co.kr/article/2021090813423798966
Last edit 2021.09.08 13:40
Telcon RF Pharmaceuticals KPM Tech The company announced on the 8th that it will start the domestic clinical trial of 'Lenzilumab', a treatment for COVID-19, which is being promoted together with the company.
Telcon RF Pharmaceuticals explained that after the Ministry of Food and Drug Safety's clinical trial plan approval in July, Seoul National University Hospital received approval from the Clinical Research Review Board (IRB) for the domestic clinical trial of lenzilumab on the 6th. To evaluate the safety, tolerability, and pharmacokinetic properties of lenzilumab in 20 Korean adults at Seoul National University Hospital.
Lenzilumab is a monoclonal antibody drug candidate that treats an immune overreaction caused by a cytokine storm, a major cause of death in COVID-19. Humanigen, which developed lenzilumab, completed the successful phase 3 clinical trial of 'LIVE-AIR' in the US and Brazil and applied for an emergency use authorization (EUA) with the US Food and Drug Administration (FDA) on May 28.
Renzilumab showed excellent efficacy in the global LIVE-AIR phase 3 clinical trial. The relative respiratory-free survival rate (SWOV) was 92% higher than that of patients treated with previously approved COVID-19 treatments such as remdesivir and corticosteroids. 54% improvement compared to placebo. In patients under 85 years of age with a CRP level of less than 150 mg/L, relative respiratory-free survival (SWOV) was improved three-fold compared to the group treated with remdesivir and corticosteroids.
Telcon RF Pharm. KPM Tech In November last year, Humanigen secured the domestic and Philippine sales rights for lenzilumab and is currently pursuing domestic clinical trials. If it passes the domestic clinical trial, it is possible to apply for a domestic import product license based on the results of the US phase 3 clinical trial. Telcon RF Pharmaceutical Division KPM Tech plans to apply for a domestic import product license as soon as lenzilumab obtains the U.S. Emergency Use Authorization (EUA).
An official from Telcon RF Pharmaceuticals explained, "As it has received IRB approval, clinical trials such as patient registration are expected to begin in earnest."
Looking good!!
I think that was Ed.
Damn...guess nobody can hold more than a day. Might add more if they dip it enough.
That will drop like .20 did with a little volume. Strong hands holding this one...very impressive.
Looking really good on nice volume!! Going to really go here soon imo!
kt
I would have done a lot better not trying to trade it...I missed that move to $5. Nice to see a little life in the OTC. Hopefully some of that money makes it over to $SMMR tomorrow!
kt
SMMR .17 keep on watch for volume. Same security counsel as MTRT with recent filings. 2.7m float
https://backend.otcmarkets.com/otcapi/company/financial-report/294698/content
kt
Very cool...sure wish I understood it. Love the picture!
kt
Quiet here too...calm before the storm? Added a bunch this morning! :)
kt
Good video explaining Israel data in natural immunity vs vaccinated.
Picked up some SMMR.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165694589
kt
I picked up a starter today. Excellent call on MTRT btw.
kt
Looks like the FDA is losing it's 2 top vaccine regulators.
Oh man. Red alert. 2 of the most senior vaccine leaders at FDA are stepping down. https://t.co/4DktoyFXFn
— Zach Brennan (@ZacharyBrennan) August 31, 2021
I wonder if this will have any bearing on our EUA?
Oh man. Red alert. 2 of the most senior vaccine leaders at FDA are stepping down. https://t.co/4DktoyFXFn
— Zach Brennan (@ZacharyBrennan) August 31, 2021
And now the top 2 FDA vaccine regulators are rumored to have resigned. Hummm....
Oh man. Red alert. 2 of the most senior vaccine leaders at FDA are stepping down. https://t.co/4DktoyFXFn
— Zach Brennan (@ZacharyBrennan) August 31, 2021
There's been a little chatter over on the warrant board. I've been trying for some .01 warrants for a flip but no luck.
SDRWW
SDRDW
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165385607